Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy
Abstract Background Inflammation plays an important role in tumor proliferation, metastasis, and resistance to chemotherapy. The systemic inflammation response index (SIRI), has been reported to be closely related to prognosis in many tumors, such as breast and gastric cancers. However, the predicti...
Main Authors: | Jie Dong, Qingqing Sun, Yueyin Pan, Nannan Lu, Xinghua Han, Qiong Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-06-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-021-08458-4 |
Similar Items
-
Survival outcomes of locally advanced gastric cancer cases with pathological complete response received neoadjuvant chemotherapy
by: Qing Hu, et al.
Published: (2021-06-01) -
Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator
by: Chen L, et al.
Published: (2020-03-01) -
An Immune-Associated Genomic Signature Effectively Predicts Pathologic Complete Response to Neoadjuvant Paclitaxel and Anthracycline-Based Chemotherapy in Breast Cancer
by: Changfang Fu, et al.
Published: (2021-08-01) -
The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery
by: Mina M. G. Youssef, et al.
Published: (2021-02-01) -
Are baseline ultrasound and mammographic features associated with rates of pathological completes response in patients receiving neoadjuvant chemotherapy for breast cancer?
by: Sarah L. Savaridas, et al.
Published: (2019-10-01)